Business Context and Reporting Period
This Form 8-K was filed by Mast Therapeutics, Inc. on September 26, 2016. The filing reports on Item 8.01 (Other Events), specifically an update regarding the Company's business plans and strategy issued via a press release. The document also details significant risks related to the continued listing of the Company's common stock on the NYSE MKT.
Key Financial Metrics
- Stockholders' Equity: $16.4 million as of June 30, 2016.
- Profitability: The Company has reported a loss from operations and a net loss in each of its five most recent fiscal years.
- 2016 Outlook: The Company expects to incur a loss from operations and a net loss for the 2016 fiscal year.
- Revenue, Cash Flow, Debt, and Liquidity: The filing text does not provide specific values for revenue, cash flow, debt levels, or liquidity ratios beyond the equity figure noted above.
Material Changes and Listing Risks
The primary material disclosure concerns the risk of delisting from the NYSE MKT due to potential non-compliance with continued listing standards. Key thresholds and risks include:
- Equity Threshold: The NYSE MKT may consider delisting if stockholders' equity falls below $6 million while the issuer has sustained losses. Mast currently has $16.4 million in equity but expects continued losses.
- Low Stock Price: If the 30-day average closing price falls below $0.20 per share, the Company may receive a deficiency letter and be required to submit a compliance plan or effect a reverse split within six months.
- Immediate Suspension: If the stock trades below $0.06 per share, the Exchange may immediately halt trading and commence delisting proceedings without an opportunity to propose a plan.
Guidance, Outlook, and Management Commentary
Management issued a press release on September 26, 2016, updating business plans and strategy, which is incorporated by reference as Exhibit 99.1. The Company explicitly states that its common stock price has been highly volatile and expects this volatility to continue. There is no assurance that the Company will maintain compliance with NYSE MKT standards. Delisting is expected to reduce trading volume and liquidity, potentially impairing the ability to raise additional capital necessary for business execution.
Investor Verification Checklist
- Verify the current 30-day average closing price of Mast Therapeutics common stock relative to the $0.20 and $0.06 thresholds.
- Review the most recent quarterly or annual report to confirm the current stockholders' equity balance against the $6 million listing requirement.
- Examine the press release filed as Exhibit 99.1 for specific details on the updated business strategy.
- Monitor for any deficiency letters or notices from the NYSE MKT regarding listing compliance.